{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:25:13Z","timestamp":1766557513973,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"United States Department of Agriculture\/National Institute of Food and Agriculture","award":["2020-67016-31543"],"award-info":[{"award-number":["2020-67016-31543"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Rift Valley fever (RVF) is a vector-borne zoonotic viral disease that causes abortion storms, fetal malformations, and neonatal mortality in livestock ruminants. In humans, RVF can lead to hemorrhagic fever, encephalitis, retinitis, or blindness, and about 1% of patients die. Since there are no registered vaccines for human use, developing RVF vaccines for use in animals is crucial to protect animals and prevent the spread of the virus from infecting humans. We recently developed a live bovine herpesvirus type 1 quadruple gene-mutant vector (BoHV-1qmv) that lacks virulence and immunosuppressive properties. Further, we engineered a BoHV-1qmv-vectored subunit Rift Valley fever virus (RVFV) vaccine (BoHV-1qmv Sub-RVFV) for cattle, in which a chimeric polyprotein coding for the RVFV Gc, Gn, and bovine granulocyte\u2013macrophage colony-stimulating factor (GMCSF) proteins is fused but cleaved proteolytically in infected cells into individual membrane-anchored Gc and secreted Gn-GMCSF proteins. Calves vaccinated with the BoHV-1qmv Sub-RVFV vaccine generated moderate levels of RVFV-specific serum-neutralizing (SN) antibodies and cellular immune responses. In the current study, we repurposed the BoHV-1qmv Sub-RVFV for sheep by replacing the RVFV Gc and Gn ORF sequences codon-optimized for bovines with the corresponding ovine-codon-optimized sequences and by fusing the sheep GM-CSF ORF sequences with the Gn ORF sequence. A combined primary intranasal-plus-subcutaneous primary immunization induced a moderate level of BoHV-1 (vector)- and vaccine strain MP12-specific SN antibodies and MP-12-specific cellular immune responses. Notably, an intranasal booster vaccination after 29 days triggered a rapid (within 7 days) rise in MP-12-specific SN antibody titers. Therefore, the BoHV-1qmv-vectored subunit RVFV vaccine is safe and highly immunogenic in sheep and can potentially be an efficient subunit vaccine for sheep against RVFV.<\/jats:p>","DOI":"10.3390\/v17030304","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:46:57Z","timestamp":1740383217000},"page":"304","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Novel BoHV-1-Vectored Subunit RVFV Vaccine Induces a Robust Humoral and Cell-Mediated Immune Response Against Rift Valley Fever in Sheep"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-0808","authenticated-orcid":false,"given":"Selvaraj","family":"Pavulraj","sequence":"first","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-5175","authenticated-orcid":false,"given":"Rhett W.","family":"Stout","sequence":"additional","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-5512","authenticated-orcid":false,"given":"Shafiqul I.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/JVI.02341-13","article-title":"Aerosolized Rift Valley fever virus causes fatal encephalitis in African green monkeys and common marmosets","volume":"88","author":"Hartman","year":"2014","journal-title":"J. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4269\/ajtmh.2007.76.795","article-title":"Spectrum of Rift Valley fever virus transmission in Kenya: Insights from three distinct regions","volume":"76","author":"LaBeaud","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.coviro.2012.02.017","article-title":"Breaking the chain: Rift Valley fever virus control via livestock vaccination","volume":"2","author":"Bird","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0140-6736(93)92128-G","article-title":"Recurrence of Rift Valley fever in Egypt","volume":"342","author":"Arthur","year":"1993","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0924-8579(02)00295-9","article-title":"Rift Valley fever: An uninvited zoonosis in the Arabian peninsula","volume":"21","author":"Balkhy","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid0812.020195","article-title":"Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000\u20132001","volume":"8","author":"Shoemaker","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4269\/ajtmh.2010.09-0293","article-title":"Risk factors for severe Rift Valley fever infection in Kenya, 2007","volume":"83","author":"Anyangu","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins","volume":"357","author":"Gerrard","year":"2007","journal-title":"Virology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., and Richt, J.A. (2017). Current Status of Rift Valley Fever Vaccine Development. Vaccines, 5.","DOI":"10.3390\/vaccines5030029"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41541-020-0166-9","article-title":"Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses","volume":"5","author":"Harmon","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-Directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J. Gen. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(90)90096-5","article-title":"Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine","volume":"8","author":"Saluzzo","year":"1990","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","article-title":"Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation","volume":"52","author":"Vialat","year":"1997","journal-title":"Virus Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3201\/eid1712.111035","article-title":"Molecular epidemiology of Rift Valley fever virus","volume":"17","author":"Grobbelaar","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ly, H.J., Lokugamage, N., Nishiyama, S., and Ikegami, T. (2017). Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185194"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mazloum, A., Van Schalkwyk, A., Babiuk, S., Venter, E., Wallace, D.B., and Sprygin, A. (2023). Lumpy skin disease: History, current understanding and research gaps in the context of recent geographic expansion. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1266759"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kitandwe, P.K., McKay, P.F., Kaleebu, P., and Shattock, R.J. (2022). An Overview of Rift Valley Fever Vaccine Development Strategies. Vaccines, 10.","DOI":"10.3390\/vaccines10111794"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wallace, D.B., Mather, A., Kara, P.D., Naicker, L., Mokoena, N.B., Pretorius, A., Nefefe, T., Thema, N., and Babiuk, S. (2020). Protection of Cattle Elicited Using a Bivalent Lumpy Skin Disease Virus-Vectored Recombinant Rift Valley Fever Vaccine. Front. Vet. Sci., 7.","DOI":"10.3389\/fvets.2020.00256"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1089\/vbz.2014.1650","article-title":"A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus-neutralizing antibody response in sheep","volume":"14","author":"Faburay","year":"2014","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pavulraj, S., Stout, R.W., Paulsen, D.B., and Chowdhury, S.I. (2024). A Quadruple Gene-Deleted Live BoHV-1 Subunit RVFV Vaccine Vector Reactivates from Latency and Replicates in the TG Neurons of Calves but Is Not Transported to and Shed from Nasal Mucosa. Viruses, 16.","DOI":"10.3390\/v16091497"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pavulraj, S., Stout, R.W., Barras, E.D., Paulsen, D.B., and Chowdhury, S.I. (2023). A Novel Quadruple Gene-Deleted BoHV-1-Vectored RVFV Subunit Vaccine Induces Humoral and Cell-Mediated Immune Response against Rift Valley Fever in Calves. Viruses, 15.","DOI":"10.3390\/v15112183"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chowdhury, S.I., Pannhorst, K., Sangewar, N., Pavulraj, S., Wen, X., Stout, R.W., Mwangi, W., and Paulsen, D.B. (2021). BoHV-1-Vectored BVDV-2 Subunit Vaccine Induces BVDV Cross-Reactive Cellular Immune Responses and Protects against BVDV-2 Challenge. Vaccines, 9.","DOI":"10.3390\/vaccines9010046"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100034","DOI":"10.1016\/j.ijidoh.2024.100034","article-title":"The importance of a One Health approach in preventing human Rift Valley fever infections in Uganda","volume":"4","author":"Nansikombi","year":"2024","journal-title":"IJID One Health"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4269\/ajtmh.22-0356","article-title":"Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease","volume":"107","author":"Watts","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/304\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:40:50Z","timestamp":1760028050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["v17030304"],"URL":"https:\/\/doi.org\/10.3390\/v17030304","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2025,2,23]]}}}